DPP-4 inhibitors also showed dose-dependent increases in beta-cell mass in a mouse model of type 2 diabetes, leading to the normalization of beta-cell mass and an improvement in islet architecture [7]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.